|
Match
|
Document |
Document Title |
|
|
6585993 |
Controlled release neurotoxin system
A biocompatible implant for continuous in vivo release of a neurotoxin over a treatment period extending from one month to five years. The implant can be made of casting a solution of a polymer,...
|
|
|
6586011 |
Microencapsulated plasminogen activators
A drug delivery system which includes a plurality of microcapsules, each microcapsule containing a plasminogen activator entrapped in a biocompatible, biodegradable, substantially water-soluble...
|
|
|
6585965 |
Hair care compositions comprising polyalkylene glycol styling agents
Hair care compositions comprise a water-soluble polyalkylene glycol having a number average molecular weight of from about 200 to about 900 and from about 4 to about 18 repeating alkylene oxide...
|
|
|
6582685 |
Hydroxyl-functionalized dendritic macromolecules in topical cosmetic and personal care compositions
The invention provides a cosmetic and personal care composition, preferably a hair styling composition such as spray, gel or mousse, comprising a hydroxyl-functionalized dendritic macromolecule....
|
|
|
6582717 |
Drug delivery composition and device
Drug delivery composition. The composition includes a polymeric material, a complexing agent, and a bioactive agent complexed with the complexing agent. The polymeric material, the complexing agent...
|
|
|
6579536 |
Sustained-release pharmaceutical preparation containing tilidine mesylate as active ingredient
The invention relates to a solid, sustained-release pharmaceutical composition for oral administration containing tilidine mesylate as active ingredient.
|
|
|
6579517 |
Cosmetic product
The present invention relates to a cosmetic composition which comprises at least one crosslinked, water-soluble or water-dispersible polyurethane formed from A) at least one polyurethane...
|
|
|
6579519 |
Sustained release and long residing ophthalmic formulation and the process of preparing the same
The present invention relates to sustained release and long residing opthalmic formulation having thermosensitivity, mucoadhesiveness, hydro gel properties and small particle size. The said...
|
|
|
6576260 |
Sustained-release form of administration containing tramadol saccharinate
Disclosed herein is sustained-release formulations of tramadol comprising tramadol saccharinate coated with at least one sustained-release coating. The sustained release formulations may also...
|
|
|
6576254 |
Polyamino acid vesicles
There is provided polymeric vesicles formed from polyamino acid derivatives for use in the delivery of therapeutic agents. The polyamino acid is modified so as to bear at least one hydrophilic...
|
|
|
6576263 |
Delivery systems using preformed biodegradable polymer compositions and methods
A preformed object for delivering an active agent for a subject, the preformed object including crosslinked protein, and methods of making and using.
|
|
|
6572894 |
Process for the production of morphologically uniform microcapsules and microcapsules that are produced according to this process
The invention relates to a process for the production of morphologically uniform microcapsules that contain peptides, proteins or other water-soluble biologically active substances as active...
|
|
|
6572889 |
Controlled release solid dosage carbamazepine formulations
A polymer or copolymer composition derived from one or more unsaturated carboxylic acids that is cross-linked and carbamazepine in conjunction with conventional materials such as fillers,...
|
|
|
6569452 |
Pharmaceutical formulations in hydroxypropylmethylcellulose capsules
An oral pharmaceutical formulation, which comprises, in a hydroxypropylmethylcellulose capsule, a camptothecin analogue dispersed or solubilized in a semi-solid matrix of a polyethyleneglycol with...
|
|
|
6569460 |
Film-coated tablet for improved upper gastrointestinal tract safety
A novel oral dosage to be delivered to the stomach comprising a safe and effective amount of an active ingredient selected from the group consisting of emepronium bromidebromide, doxycycline, and...
|
|
|
6569459 |
Method of administration of paclitaxel-plasma protein formulation
The present invention provides for a method for treating human or animal patients with paclitaxel formulation, the method comprising an intratumoral dose of a paclitaxel formulation and an...
|
|
|
6565877 |
Taste masked compositions
A taste masked composition which comprises a bitter tasting drug, a combination of two enteric polymers comprising, a methacrylic acid copolymer and a phthalate polymer is described. The...
|
|
|
6565842 |
Crosslinkable polypeptide compositions
In accordance with the present invention, there are provided rapidly crosslinkable polypeptides which are obtained upon introduction of unsaturated group(s) into the polypeptide via linkage to...
|
|
|
6565872 |
Polymeric system for drug delivery and solute separation
Described is a composite polymeric system to provide enhanced stimuli-responsiveness. The first aspect provides particles where the particles are made of stimuli-responsive polymer which responds...
|
|
|
6562375 |
Stable pharmaceutical composition for oral use
The present invention is to provide a stable pharmaceutical composition for oral use and preparation thereof in which changes are prevented in drug release at stored even under the exposure to...
|
|
|
6562361 |
Pheromone immobilized in stable hydrogel microbeads
A microbead comprising pheromone encapsulated in a coacervate shell is provided. The coacervate shell is entrained in a hydrogel microbead without chemical crosslinking. The microbeads of the...
|
|
|
6558706 |
Microencapsulated fragrances and method for preparation
This invention provides an encapsulated fragrance in which the fragrance is controlled can be released by exposing the encapsulated fragrance to a solution of a predetermined pH. The invention also...
|
|
|
6558696 |
Desoxypeganine
The invention relates to a transdermal therapeutic system (TTS) containing desoxypeganine (1,2,3,9-Tetrahydropyrrolo[2,1-b]quinazoline) as the active component, wherein the TSS includes a back...
|
|
|
6558682 |
Discontinuous films from skin care compositions
The present invention relates to substantially uniform, discontinuous films of a skin care product having a defined average particle size, particle spacing and coverage value. The films provide...
|
|
|
6558694 |
Zinc chloride unit dose packaging, applicator, and method of use in treating cancer and other skin diseases
An improved method for the treatment of melanoma and skin diseases which utilizes a zinc chloride fixative mixture is provided. The active ingredients of the fixative mixture include zinc chloride...
|
|
|
6555525 |
Microencapsulation and sustained release of oligonucleotides
This invention relates to a composition, and method of forming and using the composition, for the sustained release of oligonucleotides, in particular antisense ODNs. The sustained release...
|
|
|
6555138 |
Polyethylene glycol matrix pellets for greasy, oily or sticky drug substances
A drug delivery system for oral administration in solid dry form of greasy/oily/sticky substance(s) and pharmaceutically active substance(s) or pharmaceutically active substance(s) which...
|
|
|
6552024 |
Compositions and methods for mucosal delivery
Mucosal surface-coat-forming film dosage units containing a water-soluble hydrocolloid, an effective dose of an active agent and a mucosal adhesion enhancer; wherein the active agent is...
|
|
|
6551618 |
Compositions and methods for delivery of agents for neuronal regeneration and survival
Devices useful in the delivery of DNA encoding neurotrophic agents, anti-fibrotic agents, and related compositions are disclosed herein for use in the treatment of central and/or peripheral nervous...
|
|
|
6551612 |
Methods for modulating the axonal outgrowth of central nervous system neurons
Methods for modulating the axonal outgrowth of central nervous system neurons are provided. Methods for stimulating the axonal outgrowth of central nervous system neurons following an injury (e.g.,...
|
|
|
6548555 |
Basic drug compositions with enhanced bioavailability
A composition comprising a basic drug, a drug which forms a zwitterion, or a salt of either entity, admixed with a polymer selected from hydroxypropylmethylcellulose acetate succinate (HPMCAS),...
|
|
|
6548084 |
Controlled release compositions
A controlled release or delayed release formulation contains a selective serotonin reuptake inhibitor (SSRI) such as paroxetine.
|
|
|
6548083 |
Prolonged release active agent dosage form adapted for gastric retention
The present invention is directed to an active agent dosage form which is adapted for retention in the stomach and useful for the prolonged delivery of an active agent formulation to a fluid...
|
|
|
6541032 |
Use of finely divided dye-containing polymers PD as color-imparting constituent in cosmetic compositions
The present invention describes the use of finely divided dye-containing polymers PD in the form of an aqueous polymer dispersion or a polymer powder obtainable therefrom, the polymer matrix of...
|
|
|
6541033 |
Thermosensitive biodegradable hydrogels for sustained delivery of leptin
The present invention relates generally to the development of pharmaceutical compositions which provide for sustained release of biologically active polypeptides. More specifically, the invention...
|
|
|
6541020 |
Methods and compositions for administration of therapeutic reagents
Methods and compositions are taught that may be used to administer specific bioactive polypeptides, known as T20 and T1249 to a patient, e.g., as a method of treating a disease or disease state. In...
|
|
|
6541022 |
Mineral and cellular patterning on biomaterial surfaces
Disclosed are advantageous methods for patterning and/or mineralizing biomaterial surfaces. The techniques described are particularly useful for generating three-dimensional or contoured bioimplant...
|
|
|
6537813 |
Concurrent flow mixing methods and apparatuses for the preparation of gene therapy vectors and compositions prepared thereby
The invention relates generally to methods and apparatuses that are adapted for the preparation of gene therapeutic compositions, as well as the compositions formed thereby. The invention also...
|
|
|
6537577 |
Method of prophylaxis for bovine mastitis
A method is provided for treating bovine mastitis by applying a porous strippable polymer film containing a medicament to the udders of the bovine.
|
|
|
6534070 |
Composition with azelaic acid
The invention relates to a pharmaceutical composition having the following constituents: azelaic acid, polyacrylic acid, triacylglyceride, propylene glycol, polysorbate, soya lecithin, water and...
|
|
|
6534085 |
Phytochemicals for promoting weight loss
New dietary supplement compositions are disclosed that comprise the phytochemical Diindolylmethane (DIM), as well as its precursor, Indole-3-carbinol (I3C), and cogener, 2-(Indol-3-ylmethyl)-3,3′...
|
|
|
6534090 |
Oral osmotic controlled drug delivery system for a sparingly soluble drug
The present invention is for an oral osmotic controlled drug delivery system for a sparingly soluble drug comprising: a. a core comprising (i) finely particulate anhydrous carbamazepine (ii) a...
|
|
|
6531155 |
Granulates for cosmetic and pharmaceutical preparations
Granular materials are obtainable by pressing mixtures of at least one pulverulent, rheology-modifying, carboxyl-containing polymer as main component and at least one oil-soluble component.
|
|
|
6531154 |
Modulated release from biocompatible polymers
Sustained delivery compositions which modulate the release of incorporated prophylactic, therapeutic, and/or diagnostic agents, and methods of preparation and use thereof, are disclosed. The...
|
|
|
6531159 |
Materials eliminating cannabinoids and columns for the elimination of cannabinoids with the use of the same
The present invention provides (1) a removal material for cannabinoids present in body fluids where at least one substance from amongst substances with functional groups capable of hydrogen...
|
|
|
6531153 |
Composition with sustained release of levodopa and carbidopa
The invention relates to a pharmaceutical composition comprising a therapeutically effective amount of levodopa and of carbidopa, dispersed in a hydrophilic matrix, said composition further...
|
|
|
6528073 |
Solid cosmetic composition and uses thereof
A solid composition for topical application comprising, in an aqueous phase, a gelling system comprising (i) gellan gum, (ii) at least one other hydrocolloid chosen from the group formed by xanthan...
|
|
|
6528089 |
Method for producing solid dosing forms
Solid dosage forms are obtained by mixing at least one polymeric binder, at least one active ingredient, and, where appropriate, conventional additives to form a plastic mixture, and shaping, using...
|
|
|
6524607 |
Formulations and methods for providing prolonged local anesthesia
A formulation and methods for inducing sustained regional local anesthesia in a patient comprising a substrate comprising a local anesthetic and an effective amount of a biocompatible,...
|
|
|
6524618 |
Directly compressible extended-release matrix formulation for metformin hydrochloride
An extended-release matrx formulation capable of being directly compressed into tablets comprising metformin hydrochloride blended with specific excipients. The excipients used in the formulation...
|